Genome-wide association studies have found variation within the complement factor H gene family links to host susceptibility to meningococcal disease caused by infection with Neisseria meningitidis (Davila et al., 2010). Mechanistic insights have been challenging since variation within this locus is complex and biological roles of the factor H-related proteins, unlike factor H, are incompletely understood. N. meningitidis subverts immune responses by hijacking a host-immune regulator, complement factor H (CFH), to the bacterial surface (Schneider et al., 2006; Madico et al., 2007; Schneider et al., 2009). We demonstrate that complement factor-H related 3 (CFHR3) promotes immune activation by acting as an antagonist of CFH. Conserved sequences between CFH and CFHR3 mean that the bacterium cannot sufficiently distinguish between these two serum proteins to allow it to hijack the regulator alone. The level of protection from complement attack achieved by circulating N. meningitidis therefore depends on the relative levels of CFH and CFHR3 in serum. These data may explain the association between genetic variation in both CFH and CFHR3 and susceptibility to meningococcal disease.https://doi.org/10.7554/eLife.04008.001
Meningitis is a potentially life-threatening condition whereby the membranes that cover and protect the brain and spinal cord become inflamed. Often meningitis is caused by a viral or bacterial infection—such as infection by a bacterium called Neisseria meningitidis, also known as meningococcus. However, not everyone that comes into contact with this bacterium will develop meningitis; 40% of the population is thought to carry N. meningitidis at the back of the nasal cavity and yet show no signs of the disease.
It remains unclear why some people exposed to N. meningitidis develop meningitis while others do not; however recent research revealed that part of the immune system called the complement system plays a role in susceptibility to meningitis. The complement system is a collection of small proteins that work together to support the actions of the cells of the immune system. When activated, complement proteins trigger a cascade of events that helps to destroy the pathogen.
Several mechanisms exist to keep the complement proteins in check—for example, a protein called complement factor H (or CFH) protects host cells from being attacked by other complement proteins. N. meningitidis can undermine the complement system by expressing a protein that binds to CFH and firmly fixes CFH to its cell surface. While the CFH-binding protein helps explain why some people are unable to mount the appropriate immune response to infection by N. meningitidis, it does not explain why some carriers of the pathogen do not develop meningitis.
Now, Caesar et al. have examined a protein called CFH related-3 (or CFHR3), and discovered that CFHR3 competes with CFH for the binding protein on N. meningitidis. CFHR3 is structurally similar to CFH, but it is unable to regulate or silence the complement system. Caesar et al. explain that susceptibility to meningococcal disease is determined by how much CFH and how much CFHR3 each individual has, and that those with less CFHR3 will be more susceptible to N. meningitidis. An individual's genes will affect how much CFH and CFHR3 they have, while the genes of the bacterium can influence how strongly the CFH binding protein binds to either of these human proteins. Caesar et al. suggest that these two factors determine whether or not an individual will develop meningitis or simply carry the bacterium without any ill effects.
Caesar et al.'s findings highlight the different ways that people's genes can determine how they respond to an invading pathogen. The findings also suggest that it is important to consider variation in the levels of these complement proteins across a population when planning immunisation schedules.https://doi.org/10.7554/eLife.04008.002
Neisseria meningitidis is an important cause of rapidly progressive septicaemia and meningitis in children and young adults (Stephens et al., 2007); case fatality rates for bacteraemic disease remain at around 10%, and a significant proportion of survivors are left with long-term sequelae (Vyse et al., 2013). For most individuals, however, this human-specific bacterium is primarily a non-pathogenic commensal of the nasopharynx, and up to 40% of the population are healthy carriers (Caugant and Maiden, 2009). The mechanisms underlying human genetic influences that govern the development of invasive disease or asymptomatic carriage are incompletely understood. It is known, however, that complement activation is critical for protection against disease, evident from the susceptibility of individuals with genetic deficiency of either the alternative complement pathway (AP) or terminal pathway activation, and among those receiving therapy that prevents terminal pathway activation (Schneider et al., 2007; McKeage, 2011). Amongst several strategies that promote complement evasion, N. meningitidis recruits the human negative complement regulator, complement factor H (CFH), to its surface by expressing factor H binding protein (fHbp) (Schneider et al., 2006, 2009; Madico et al., 2007). fHbp can be divided into three variant groups (V1, V2, and V3), which have >85% sequence identity within the groups but only 60–70% similarity between groups (Masignani et al., 2003; Brehony et al., 2009). fHbps from all variant groups bind CFH with a KD in the low nanomolar range (Johnson et al., 2012). Therefore, it is significant that the only single nucleotide polymorphisms (SNPs) associated with meningococcal disease in a recent genome-wide association study (GWAS) were those among the CFH–CFHR locus. These included SNPs within CFH and the downstream gene, CFHR3 (Davila et al., 2010). While CFH has been extensively studied (reviewed in Makou et al. (2013)), the role of the serum protein CFHR3 has not been unambiguously established (reviewed in Jozsi and Meri (2014)).
We recently demonstrated that three of the five CFHR proteins (i.e., CFHR1, 2, and 5) compete with CFH for binding to C3b on heterologous erythrocytes, thereby promoting complement activation (Goicoechea de Jorge et al., 2013). Given the association of CFHR3 with meningococcal disease (Davila et al., 2010), we investigated whether this protein and CFHR4 also act as CFH antagonists in this assay. We generated full-length CFHR3 and CFHR4B (which both consist of five complement control protein [CCP] domains, Figure 1A) and truncated versions of these proteins, and we examined their ability to influence complement activation by the AP, which is regulated by CFH (Makou et al., 2013). Erythrocyte haemolysis assays demonstrate that CFHR3 and CFHR4B are also CFH antagonists on this surface, with their two C-terminal domains enabling them to compete with CFH for binding sites on cell complement fragments such as C3b (Figure 1B, Figure 1—figure supplement 1A,B). Additional cell-surface recognition sites within other domains (Figure 1A) increase the activity of the full-length CFHR3 and CFHR4B as competitive antagonists of CFH (Figure 1B) at physiologically relevant concentrations of ∼1 μM (Fritsche et al., 2010; Hebecker and Jozsi, 2012).
N. meningitidis fHbp recruits CFH by high-affinity interactions primarily with domain 6 of CFH (CFH6) with some limited contact to CFH7 (Schneider et al., 2009). Since the first domains of the CFHRs share between 40% to 90% identity with CFH6 (Figure 1A, Figure 2), we next investigated whether fHbp also bound the CFHRs. Our findings (Figure 1C) demonstrate that CFHR3 binds fHbp with a KD of ∼3 nM, similar to affinities for CFH (Schneider et al., 2009; Johnson et al., 2012); no significant binding was detected for the other CFHRs with fHbp. Of note, the first two domains of CFHR3 (CFHR312; domain 1 shares 91% identity with CFH6, Figure 1A) and the full-length protein bind fHbp with similar affinities (Figure 1E, Figure 1—figure supplement 1C,D). Furthermore, a point mutation within fHbp (E255A) that reduces binding to CFH by more than three orders of magnitude (Johnson et al., 2012) similarly reduces CFHR3 binding (Figure 1E). The nature of the CFH and CFHR3 interactions with fHbp are therefore similar, with these complement factors occupying overlapping sites on fHbp, which is consistent with the high degree of conservation of their fHbp binding sites (Figure 2).
Next we investigated whether CFHR3 binds to the surface of N. meningitidis. We generated a CFHR3-specific monoclonal antibody (mAb) (Figure 3—figure supplement 1), designated HSL1. By flow cytometry we demonstrated that serum CFHR3 bound N. meningitidis M1239 (which expresses V3.28 fHbp) in a fHbp-dependent manner. No binding was detected following incubation of bacteria in sera from an individual homozygous for an allele in which there is combined deletion of the CFHR1 and CFHR3 genes (ΔCFHR3/1) (ΔCFHR3/1, Figure 3A,B,C). We therefore tested the functional consequences of CFHR3 binding by comparing the effect of adding full length or domains of CFHR3 to N. meningitidis prior to incubation in normal human serum (NHS). Addition of full-length CFHR3 or CFHR312, which contains the fHbp binding site (Figure 1C) but has no CFH antagonist activity (Figure 1B), resulted in significantly reduced bacterial survival (CFHR3 51%; CFHR312 70%; no protein or CFHR345 83%, Figure 3D); in contrast, CFHR3 had no detectable effect in the presence of heat-inactivated NHS (which lacks complement activity, Figure 3D). Full-length CFHR3 has a more marked effect on bacterial survival than CFHR312, consistent with the ability of the full-length CHHR3 to bind to C3b deposited on the bacterial surface (via CFHR345) as well as competing with CFH for fHbp (via CFHR312). As CFHR345 does not bind fHbp (Figure 1C), its CFH antagonist activity is not effectively localized to the meningococcal surface, providing an explanation for why these domains have no effect on bacterial survival (Figure 3D). Similarly, addition of CFHR3 has no effect on serum survival of bacteria that do not express any CFH-binding protein (Figure 3—figure supplement 2A, N. meningitidis strain lacking fHbp expression; Figure 3—figure supplement 2B, Escherichia coli strain with no expression of any CFH-binding protein).
The finding that CFHR3 binding impairs bacterial survival in NHS led us to consider whether fHbp can distinguish between the limited sequence differences between CFH and CFHR3 to generate specificity for CFH. We previously identified a series of alanine substitutions in fHbp that significantly reduce or ablate CFH binding (Johnson et al., 2012). Therefore, we measured the contribution of fHbp residues to interactions with CFHR3 to determine whether any amino acid changes altered the specificity of fHbp for the two complement factors (Figure 4A, Figure 4—source data 1). The results demonstrate that the majority of mutations that impair CFH binding (Johnson et al., 2012) also significantly reduce CFHR3 binding, so do not alter specificity for CFH; point mutations at only a few sites led to modest alterations in specificity at levels that are unlikely to be physiologically relevant given the relative affinities for CFHR3/CFH and their abundance in serum (CFHR3 1–1.6 μM [Fritsche et al., 2010; Hebecker and Jozsi, 2012]; CFH 1–4 μM [Hakobyan et al., 2008]). Interestingly the V1 fHbp used as the background for the mutations (V1.1) did reveal a degree of specificity for CFH over CFHR3 (in the order of ∼20-fold) in contrast to V2 and V3 fHbps, suggesting that certain fHbps can discriminate between CFH and CFHR3.
To investigate this further, we measured binding of CFH and CFHR3 to 25 naturally occurring fHbps that are prevalent in disease isolates of N. meningitidis (Figure 4B, Figure 4—source data 1) (Lucidarme et al., 2009). This demonstrated that V2 and V3 fHbps displayed no selective affinity for CFH over CFHR3 (average selectivity being 1.8 ± 1.4 and 2.4 ± 1.0, respectively). In contrast, V1 fHbps had lower affinities for CFHR3 compared to CFH (average selectivity 8.9 ± 4.6-fold), with 12 of the 14 V1 fHbp variants binding CFH 5- to 20-fold more tightly than CFHR3. Modeling the effect on the occupancy of fHbp with CFH indicates that certain V1 fHbps will be bound by CFH in the physiological situation regardless of CFHR3 levels (Figure 5). To examine whether this has any functional consequence, we examined complement AP killing of isogenic strains expressing fHbp sequences with different abilities to discriminate between CFH and CFHR3 (Figure 4C); AP killing was assessed to exclude any confounding influence of antibodies in sera preferentially recognizing different fHbps. Bacteria expressing V3.28 fHbp, which has identical affinities for CFH and CFHR3, were the most sensitive to AP killing, while the strain expressing the V1.1 fHbp sequence (which has ∼20-fold tighter binding to CFH than CFHR3) was the least sensitive; bacteria with fHbps with intermediate CFH specificity displayed intermediate levels of protection. This suggests that, even though the most specific fHbps bind CFHR3 with a KD significantly below the physiological concentration (Figure 4—source data 1), the ability of fHbp to favour CFH binding promotes bacterial survival and offers a potential explanation for the prevalence of strains expressing V1 fHbp causing invasive disease (Lucidarme et al., 2009).
To define the basis for the effect of CFHR3 on bacterial survival, we next examined the impact of CFHR3 on levels of CFH bound to the bacterial surface. N. meningitidis incubated in the ΔCFHR3/1 sera acquire high levels of CFH on the bacterial surface (Figure 6A,B,C). However, addition of recombinant CFHR3 reduces the amount of bound CFH in a dose-dependent manner, demonstrating antagonism between CFH and CFHR3 for binding to the bacterial surface. When the amount of recombinant CFHR3 is added at approximately equimolar levels to those in NHS, the level of CFH bound on the bacterial surface is only half that seen in the CFHR3-deficient sera (1–1.6 μM [Fritsche et al., 2010]).
In summary, our work demonstrates that susceptibility to an important infectious disease is governed by the competition between two complement factors with opposing effects (CFH and CFHR3) for overlapping binding sites on a single pathogen molecule. Our data predict that the risk of developing meningococcal disease will be governed by the relative abundance of CFH and CFHR3 in individuals and the affinity of these molecules for the specific fHbp on the bacterial surface (Figure 6D). It is notable that the ΔCFHR3/1 allele has a high prevalence in sub-Saharan Africa (Holmes et al., 2013) where there are high rates of epidemic disease. Our mechanism is consistent with this association, since this allele would enhance the interaction between CFH and fHbp and favour pathogen survival. This is particularly true as the ΔCFHR3/1 deletion is associated with increased plasma CFH levels, most likely due to the loss of a regulatory locus (Ansari et al., 2013; Zhu et al., 2014). However, host polymorphisms in CFHR3 might have less impact on strains of bacteria that express fHbp that more selectively bind CFH. Therefore, susceptibility to meningococcal disease will be influenced by polymorphisms and copy number variation affecting two host complement factors and by the relative affinity of fHbp on an infecting strain for CFH and CFHR3. This illustrates why genetic association studies in infectious diseases are likely to be technically challenging since these will be influenced not only by sequence and structural variation within the host but also by genetic variation in pathogen.
Sequences encoding CFHR145, CFHR312, CFHR345 and CFHR445 were amplified using primer pairs CFHR1-4-Forward(5′-GAAGGAGATATACCATGACGGGAAAATGTGGGCC-3′)/CFHR1-5-Reverse(5′-GGCCCACATTTTCCCGTCATGGTATATCTCCTTC-3′), CFHR3-1-Forward(5′-GATATACATATGAAACCTTGTGATTTTCCAGACATTAAAC-3′)/CFHR3-2-Reverse(5′-GGATCCTCGAGCTAACGGATGCATCTGGGAGTAG-3′), CFHR3-4-Forward(5′-GGCAGCCATATGTCAGAAAAGTGTGGGCCTCCTC-3′)/CFHR3-5-Reverse(5′- CGGATCCTCGAGTTATTCGCATCTGGGGTATTCCACTATC-3′) and CFHR3-4-Forward/CFHR4-5-Reverse(5′- CGGATCCTCGAGTTATTCGCATCTGGGGTATTCCACTATG-3′), respectively. The sequence encoding CFHR589 was amplified using primer pair CFHR5-8-Forward(5′-CCACATATGGCATATTGTGGGCCCCCTCCATC-3′)/CFHR5-9-Reverse(5′-GGATCCTCGAGTCATTCACATATAGGATATTCAAATTTC-3′). Inserts were cloned between the NdeI and XhoI sites of a modified version of vector pET-15b (Novagen, Merck Millipore, Billerica, MA), which has the NcoI site replaced with an NdeI site.
A vector encoding FH19–20 was generated from that encoding CFHR145 using site-directed mutagenesis with primers L183S-Forward(5′-GGACAGCCAAACAGAAGCTTTATTCGAGAACAGGTGAA-3′)/L183S-Reverse(5′-TTCACCTGTTCTCGAATAAAGCTTCTGTTTGGCTGTCC-3′) and A189V-Forward(5′-TTTGAGAACAGGTGAATCAGTTGAATTTGTGTGTAAACGGG-3′)/A189V-Reverse(5′- CCCGTTTACACACAAATTCAACTGATTCACCTGTTCTCAAA-3′).
The gene encoding full-length CFHR3 was amplified using primers encoding a histidine (His) tag (CFHR3-Forward 5′-ATTCGCGGCCGCCCCACCATGTTGTTACTAATCAAT-3′ and CFHR3-Reverse 5′-CACCATCACCATCACCATTAGCTCGAGGAA-3′) and cloned into a modified version of the pCAGGS plasmid (Shimizu et al., 1999) bearing the CMV-EI enhancer, the chicken β-actin promoter, and intron 1 of the simian virus 40 poly(A) signal.
The gene encoding full-length CFHR4 was amplified using primer pair CFHR4-Forward(5′- GGACTGTCTAGAGACTCAGATCCCCATCCGCTCAAGCAGGCCACCATGTTGTTACTAATCAATGTCATTCTGACC-3′)/CFHR4-Reverse(5′ GTGTCGGGTCGACCCTTCGCATCTGGGGTATTCCAC-3′) prior to ligation into vector pEF-BOS (Mizushima and Nagata, 1990) between the XbaI and SalI sites giving a C-terminal hexahistidine tag.
Recombinant His-tagged fHbp was prepared from a selection of natural variant fHbps and alanine substitution mutants of fHbp V1, V2, and V3 as described previously (Johnson et al., 2012). All three variant types were represented within 27 natural fHbp variant sequences, numbered according to an allele ID code as detailed on the Neisseria Multi Locus Sequence Typing website (http://pubmlst.org/neisseria/) developed by Keith Jolley and sited at the University of Oxford (Jolley and Maiden, 2010).
CFH67 was prepared as previously described (Prosser et al., 2007). CFH19–20, CFHR145, CFHR345, CFHR445, and CFHR589 were expressed in E. coli and refolded from inclusion bodies prior to size exclusion chromatography (Superdex S-75, GE Healthcare, Little Chalfont, UK, buffer 50 mM Tris pH 7.5, 150 mM NaCl) using the same method previously described for CFHR245 (Goicoechea de Jorge et al., 2013). CFHR112 was expressed in Kluyveromyces lactis as previously described (Goicoechea de Jorge et al., 2013). CFHR312 was prepared in an identical manner to CFH67 with substitution of the final size exclusion chromatography step for purification using heparin affinity (Heparin FF column, GE Healthcare, buffer A: 50 mM Tris pH 7.5, 10 mM NaCl, buffer B: 50 mM Tris pH7.5, 1 M NaCl, elution gradient: 50% over 15 CV).
Recombinant His-tagged CFHR3 was expressed in HEK293 cells using Lipofectmine 2000 (Invitrogen) as per manufacturer's instructions. Recombinant His-tagged CFHR3 supernatant was purified by a single affinity chromatography step using a His-Trap HP (GE Healthcare) as per manufacturer's instructions. The bound protein was eluted with 500 mM Imidazole and then dialysed against 10 mM sodium phosphate pH7.8.
CFHR4 was expressed transiently in cell line HEK293S GntI−/− from vector pEF-BOS. Transfection was performed using 293Fectin (Life Technologies, Carlsbad, CA) as per the manufacturers instructions. Cells were cultured in suspension using Freestyle 293 Expression medium (Life Technologies) at 37°C with 10% CO2 for 96 hr prior to harvesting the media. CFHR4 was purified from the media using a Ni-NTA column (Qiagen) as per the manufacturer’s instructions. Purified protein was dialysed into phosphate buffered saline (PBS) prior to use.
All surface plasmon resonance measurements were made at 25°C using either a Biacore 3000 (GE Healthcare) or ProteOn XPR36 (BioRad, Hercules, CA) instrument with buffer HBS-EP (10 mM Hepes pH7.4, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant-P20). Proteins were immobilised via primary amine coupling with a mock activated–deactivated reference channel included on each. Measurement of the affinity between CFHR312 and fHbp V3 was performed by immobilising approximately 1200 RU fHbp on the surface of a CM5 sensor chip (GE Healthcare). Dilution series of CFHR312 ranging from 12.5 nM–0.2 nM were flowed over the surface at 40 µl/min using KINJECT with a contact time of 300 s and dissociation time of 1200 s. The surface was regenerated with 10 mM glycine pH 3.0 between each injection. Curves were mock subtracted and fit with a 1:1 Langmuir model using BiaEvaluation (GE Healthcare).
Analysis of binding of CFHRs and CFHR fragments to fHbp V3 was performed using a CM5 chip with approximately 1700 RU fHbp immobilised. 100 µl of each analyte at a minimum concentration of 200 nM was flowed over the surface at 20 µl/min using the KINJECT command with a dissociation time of 400 s. The surface was regenerated using 10 mM glycine pH 3.0 between injections. Curves were mock subtracted using BiaEvaluation.
Measurement of the large panel of fHbp mutants was performed by immobilization of the proteins on ProteOn GLM sensor chips (BioRad). Increasing concentrations of CFHR312 or fH67 were injected over the flow channels at 60 µl/min for 240 s and allowed to dissociate for 1200 s. The surface was regenerated with 10 mM glycine pH 3.0 between each injection. Curves were mock subtracted and fit with a 1:1 Langmuir model using ProteOn manager software (BioRad).
fHbp V3 was labelled using the RED-NHS labelling kit (NanoTemper Technologies, Munich, Germany) as per the manufacturer’s instructions. Dilution series of CFHR312 in the range of 740 nM–23 pM were set up using HBS-EP. Each sample also contained 4 nM labelled fHbp. Thermophoresis was measured using a Monolith NT.115 instrument (NanoTemper Technologies) at 22°C utilising hydrophilic treated capillaries (NanoTemper Technologies), 80% LED power and 60% LED power. All data were measured in triplicate across three independent dilution series. Data were analysed using the signal from Thermophoresis + T-Jump (NT Analysis software version 1.5.41, NanoTemper Technologies).
The effect of CFHR3, CFHR312, CFHR345, CFHR4, and CFHR445 upon AP activation was assessed using haemolytic assays that were performed in an identical manner to that described in Goicoechea de Jorge et al. (2013). All measurements were performed in triplicate and are presented as haemolysis relative to the level of lysis without addition of CFHR proteins (0%) and 100% lysis by H2O. Haemolytic assays with CFH-deficient serum (CompTech, Tyler, TX) were performed with 5% serum.
N. meningitidis was grown on brain heart infusion (BHI, Oxoid) agar supplemented with 5% Levinthal's base (500 ml defibrinated horse blood autoclaved with 1 l BHI) overnight at 37°C in the presence of 5% CO2 (Lucidarme et al., 2009; Jongerius et al., 2013). M1239Δfhbp was constructed as previously (Jongerius et al., 2013) and isogenic strains were constructed by complementing the strains with fHbp V1.P1, V1.P14, V2.P22, or V3.P28 amplified using primers listed in Table 1. Polymerase chain reaction products were ligated into pGCC4 (Mehr and Seifert, 1998). Transformation of N. meningitidis strain M1239Δfhbp was performed as described previously (Exley et al., 2005).
NHS were obtained by collecting whole venous blood and allowing it to coagulate at room temperature for 60 min before centrifuging at 3000×g for 20 min at 4°C. Sera were heat inactivated at 56°C for 30 min prior to use. N. meningitidis was grown overnight on BHI agar, re-suspended in PBS then diluted to 1 × 105 CFU/ml in DMEM (Sigma). A total of 1 × 104 CFU of bacteria were pre-incubated with 1 µM CFHR3, 1 µM CFHR3 domains or PBS for 10 min prior to incubation with 5% human sera or 5% heat inactivated sera for 30 min at 37°C in the presence of CO2. Bacterial survival was determined by plating onto BHI agar. Relative survival was calculated from samples containing no CFHR3 and incubated with heat-inactivated sera and expressed as percentage survival.
For the AP assays, bacteria were grown on BHI agar supplemented with 1 mM IPTG. Other complement pathways were inhibited by the addition of 5 mM MgCl2/10 mM EGTA, and bacteria were incubated in 25% sera as above. Statistical significance was tested using the one-way ANOVA multiple comparisons as implemented in GraphPad Prism v.6.0 (GraphPad Software Inc.) to compare means ±S.E.M. using a p < 0.01 cutoff for significance.
Recombinant CFHR345 conjugated to KLH (Imject, Pierce) was used as an antigen. Female BALB/c mice were immunised with 100 μg of recombinant protein emulsified in TitreMax Gold (Sigma, UK) subcutaneously on day 1, then with 100 μg of CFHR345 in PBS intraperitoneally (IP) on days 21 and 42. A booster of 200 μg of recombinant protein in PBS was given IP 3 days prior to cell fusion on day 63. NS0 myeloma cells were grown in RPMI 1640 (Lonza, UK) supplemented with 10% foetal bovine serum (FBS, Sigma, UK), 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 μg/ml) (Galfre and Milstein, 1981). Splenectomy was performed on day 66, and splenocytes fused to NS0 myeloma in polyethylene glycol (PEG 1500, Roche, UK) (Mason et al., 1983). Fused cells were then plated into 24-well plates in RPMI 1640 containing 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 μg/ml), and 1% Ultroser G (Pal France). After 24 hr, 2% hypoxanthine adminopterin thymidine (HAT, Life technologies) was added to the wells. Hybridoma clone supernatants were screened by ELISA against recombinant CFHR345. Positive clones were re-plated and grown for a further 5 days before screening again by ELISA against the CFHR345 and all five CFHR proteins. Positive hybridoma cells were sub-cultured into 96-well plates at a concentration of 1 cell per well in RPMI 1640 containing 10% FBS, 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 μg/ml), Ultroser G (1%), and BM Condimed H1 (1%, Roche, UK). After 5 days, wells containing single colonies were screened as before.
Bacteria (1 × 109 CFU/ml) were fixed in 1 ml of 3% formaldehyde for 2 hr then washed with PBS. To evaluate CFHR3 binding, 5 × 107 CFU/ml were re-suspended in 10 μl of NHS or 10 µl of sera from an individual with ΔCFHR3/1 for 30 min at room temperature. After two washes in 0.05% BSA/PBS, binding was detected following incubation with the anti-CFHR3 mAb (HSL1 this study) for 30 min at 4°C in 50 μl of PBS. Cells were washed twice in 0.05% BSA, then resuspended in 50 μl of goat anti-mouse IgG-Alexa Fluor 647 conjugate (1 in 1000 dilution in PBS; Molecular Probes, Life Technologies) and incubated for 30 min at 4°C. Samples were run on a FACSCalibur (BD Biosciences), and at least 104 events recorded before results were analysed by calculating the geometric mean FL-4 in FlowJo vX software (Tree Star).
To evaluate the influence of CFHR3 on CFH binding to bacteria, 5 × 107 CFU/ml of N. meningitidis M1239 were incubated in 10 µl of ΔCFHR3/1 sera and twofold dilutions of recombinant full-length CFHR3 (from 1 µM) for 30 min at room temperature. CFHR3 binding was detected with the anti-CFHR3 mAb (HSL1 this study) or an anti-human CFH mAb (MRC OX24, 0.1 μg/ml) (Sim et al., 1983), followed by incubating with goat anti-mouse IgG-Alexa Fluor 647 conjugate (1 in 1000 dilution in PBS; Molecular Probes, Life Technologies) and analysed by flow cytometry. At least 104 events were recorded before results were analysed by calculating the geometric mean FL-4 in FlowJo vX software (Tree Star). Maximum fluorescence for CFHR3 was normalised to the addition of 1 µM exogenous CFHR3, whereas the maximum fluorescence for CFH was normalised without the addition of exogenous CFHR3. Statistical significance was tested using the one-way ANOVA multiple comparisons as implemented in GraphPad Prism v.6.0 (GraphPad Software Inc.) to compare means ±S.E.M. using a p < 0.01 cutoff for significance.
Variation of the factor H-binding protein of Neisseria meningitidisMicrobiology 155:4155–4169.https://doi.org/10.1099/mic.0.027995-0
Available carbon source influences the resistance of Neisseria meningitidis against complementThe Journal of Experimental Medicine 201:1637–1645.https://doi.org/10.1084/jem.20041548
Preparation of monoclonal antibodies: strategies and proceduresMethods in Enzymology 73:3–46.
Dimerization of complement factor H-related proteins modulates complement activation in vivoProceedings of the National Academy of Sciences of USA 110:4685–4690.https://doi.org/10.1073/pnas.1219260110
Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degenerationInvestigative Ophthalmology & Visual Science 49:1983–1990.https://doi.org/10.1167/iovs.07-1523
Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b proteinThe Journal of Biological Chemistry 287:19528–19536.https://doi.org/10.1074/jbc.M112.364471
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870The Journal of Experimental Medicine 197:789–799.https://doi.org/10.1084/jem.20021911
BookProduction of monoclonal antibodies for immunocytochemical useIn: Petrusz B, editors. Techniques in immunocytochemistry II. New York: Academic Press. 175.
Expression, purification, cocrystallization and preliminary crystallographic analysis of sucrose octasulfate/human complement regulator factor H SCRs 6-8Acta Crystallographica Section F. Structural Biology and Crystallization Communications 63:480–483.https://doi.org/10.1107/S1744309107020052
Functional significance of factor H binding to Neisseria meningitidisJournal of immunology 176:7566–7575.https://doi.org/10.4049/jimmunol.176.12.7566
Interactions between Neisseria meningitidis and the complement systemTrends in Microbiology 15:233–240.https://doi.org/10.1016/j.tim.2007.03.005
Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDACNature 399:483–487.
Monoclonal antibodies against the complement control protein factor H (beta 1 H)Bioscience Reports 3:1119–1131.https://doi.org/10.1007/BF01120205
The burden and impact of severe and long-term sequelae of meningococcal diseaseExpert Review of Anti-Infective Therapy 11:597–604.https://doi.org/10.1586/eri.13.42
Variants in complement factor H and complement factor h-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA NephropathyJournal of the American Society of Nephrology.
Feng ShaoReviewing Editor; National Institute of Biological Sciences, China
eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see review process). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.
Thank you for sending your work entitled “Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility” for consideration at eLife. Your article has been favorably evaluated by Tadatsugu Taniguchi (Senior editor) and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.
The Reviewing editor and the other reviewers discussed their comments before reaching the decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.
This interesting and clinically relevant study provides data that allow a plausible explanation of human variability in outcomes of Neisseria meningitidis infection by defining both bacterial and host components that can vary to determine whether complement-mediated killing occurs within human serum. Previously, it is known that fHbp, a surface exposed lipoprotein from N. meningitidis, can bind to complement factor H (CFH), playing an important role of evasion of complement-mediated killing of the bacteria. Because of this, study of fHbp binding to CFH has important implications in vaccine design and improvement. In this work, the authors pursue a result from a genome-wide association study (GWAS) study of N. meningitidis that implicates human variability in CFHR3 as associated with host susceptibility. They demonstrate that CFHR3 could also bind to fHbp with a similar affinity as CFH and went further to show that the binding surface on fHbp by CFH and CFHR3 completely overlaps. They then demonstrate convincingly that CFHR3 promotes complement activation by competing with CFH on the bacterial surface. Finally, they further propose a model that the relative levels of two complement and related proteins (CFH and CFHR3) in the circulation system is a critical factor for determining the host susceptibility to meningococcal disease. In general, the study is very clearly written and provides an exciting and generally interesting observation. The concept proposed is novel and highly interesting given that there are five CFHR proteins that are often involved in binding to surface proteins of various bacterial pathogens. The paper is potentially suitable for eLife after addressing the following points.
1) As a rationale for the study and also a clinically relevant conclusion, the authors point to a recent GWAS study showing linkage disequilibrium to a specific single nucleotide polymorphism (SNP) and hence indicating the possibility that the linkage could be a result of deletion of CFHR3/CFHR1. In reading the Nature Genetics report, though, it does not appear that the CFHR3/CFHR1 deletion itself is linked to disease risk, but the association is rather to the CFHR3 SNP that is outside of the deleted region. The authors should clarify to readers the exact understanding of the relationship between N. meningitidis risk and the CFHR3/CFHR1 deletion. If that connection is not established through population studies then what could be the proposed mechanistic link to the CFHR3 polymorphism(s)?
2) In contrast to the binding assays, the actual differences in relative survival of N. meningitidis in the presence and absence of CFHR3 are rather modest (Figure 3d, e, 4c). In addition, only one serum concentration and one protein concentration is used. In what is likely to be optimized conditions, the differences are <two-fold. Given the non-linear activities of the complement alternative pathway (AP) and amplification loop, it is not certain how modest changes in serum concentration would impact the results with different CFHR3/CFH ratios. To address this issue, the authors should present results of killing assays using a range of serum and protein concentrations. The authors should also include the fHbp-deficient N. meningitidis mutant strain as well as complementation by E255A as controls. Moreover, statistics should be also performed on the differences between normal human serum (NHS) and heat-inactivated serum with different CFHR3 proteins with p values calculated.
3) Serum killing assays are of course only an approximation of the complex bacterial protective response in vivo. Although there are no good animal models of human CFHR activities, inclusion of human neutrophils can provide a more complete analysis of the relationship between serum complement-bactericidal activity and bacterial killing (see for instance Ross et al, J Infect Dis. (1987) 155 (6): 1266-1275). The authors should perform such combined serum- and cell-based assays in which a more complete role of complement, and in particular its C3 fragment receptors on neutrophils, can be evaluated for their contribution to bacterial killing.
4) CFH and CFHR3 are generally considered to have similar function of negatively regulating the complement activity. However, the authors indicate here and in previous studies that this perception is wrong and CFHR3 can compete with CFH to bind the C3b complex and therefore counteract the negative function of CFH. The authors should go beyond the erythrocyte haemolysis assay in Figure 1b and examine the general function of CFHR3 in serum-mediating killing of bacteria that have nothing to do with CFH/CFHR3 binding (also consider using their CFHR3-deficient sera). This is particularly important in that pathogens exhibit a wide variety of mechanisms to evade the in vivo immune response, most of which do not directly target the complement system. In that context, additional support for an important role by this mechanism would add substantially to the relevance and potential impact of the study.
5) According to the authors' model, the function of CFHR3 should depend on the presence of CFH. However, there were no direct evidences demonstrating this point. Can CFH-deficient serum be found? If not, is it possible to deplete or block CFH by using CFH-specific antibody? In the latter, the authors can then examine whether exogenous CFHR3 still has any effect on complement-mediated killing in the sera in the absence of CFH function.https://doi.org/10.7554/eLife.04008.014
1) As a rationale for the study and also a clinically relevant conclusion, the authors point to a recent GWAS study showing linkage disequilibrium to a specific SNP and hence indicating the possibility that the linkage could be a result of deletion of CFHR3/CFHR1. In reading the Nature Genetics report, though, it does not appear that the CFHR3/CFHR1 deletion itself is linked to disease risk, but the association is rather to the CFHR3 SNP that is outside of the deleted region. The authors should clarify to readers the exact understanding of the relationship between N. meningitidis risk and the CFHR3/CFHR1 deletion. If that connection is not established through population studies, then what could be the proposed mechanistic link to the CFHR3 polymorphism(s)?
The GWAS study by Davila et al. did not show an association with the CFHR3‐1 deletion polymorphism as evident by the lack of an association between macular degeneration and the typed rs6677604 SNP (Davila et al., Nature Genetics 2010, Supplemental data Table 3). This SNP tags the CFHR3–1 deletion in many populations. The statistically significant associations in the GWAS study consisted of SNPs within CFH, within CFHR3 and within CFHR1, although the latter failed genotyping in one of the cohorts [Spanish] so was not included in the combined analysis (Davila et al., Nature Genetics 2010, Table 2). On the data presented it was not possible to conclude that the identified SNPs were causal because many of them were in linkage disequilibrium across the CFH–CFHR locus. In fact Davila et al. make the point “these CFH and CFHR SNPs are statistically indistinguishable from one another, and further work, such as deep resequencing, may be needed to identify the causal variant or variants within the associated region if the currently identified SNPs are not the functional variants”. What we can robustly conclude from the existing data is that variation within the CFH–CFHR locus influences susceptibility to macular degeneration. This includes variation within CFH (not unexpected from observations from complement deficiency states) and within the CFHR protein family (unexpected). Our functional studies support an association with variation within CFHR3. We have modified the text to reflect these comments.
2) In contrast to the binding assays, the actual differences in relative survival of N. meningitidis in the presence and absence of CFHR3 are rather modest (Figure 3d, e, 4c).
The difference in survival on the addition of CFHR3 is approximately 40% in the assay we performed that was over the course of 30 minutes. Although the difference appears modest to the reviewer, this will be marked during bacteraemia over hours in an infected individual. For example, over two hours the presence of CFHR3 would result in 88% less in survival of bacteria in the presence of CRHR3 compared to an individual with ΔCFHR3‐CFHR1 (and a 95% difference over 3 hrs).
In addition, only one serum concentration and one protein concentration is used. In what is likely to be optimized conditions, the differences are <two-fold. Given the non-linear activities of the AP and amplification loop, it is not certain how modest changes in serum concentration would impact the results with different CFHR3/CFH ratios. To address this issue, the authors should present results of killing assays using a range of serum and protein concentrations. The authors should also include the fHbp-deficient N. meningitidis mutant strain as well as complementation by E255A as controls.
As suggested by the reviewers, we have evaluated the effect of the different concentrations of CFHR3 on the survival of wild‐type bacteria and the isogenic fHbp mutant. The amount of serum in both the NHS and AP assays was kept constant to give approximately 80% bacterial survival without additional CFHR3; this enables the impact of this de‐regulator (which was expected to decrease survival) to be determined. The results demonstrate that the effect of CFHR3 (Mol Microbiol. 2011 Sep;81(5):1330-42; Nat Rev Microbiol. 2012 Jan 31;10(3):178-90) on meningococcal survival is dose and fHbp dependent (Figure 1). We now include these results as supplementary data (Figure 3–figure supplement 2, panel a).
Moreover, statistics should be also performed on the differences between NHS and heat inactivated serum with different CFHR3 proteins with p values calculated.
We have added the relevant statistical analyses to the Figure (Figure 3D in our revised manuscript) as requested.
3) Serum killing assays are of course only an approximation of the complex bacterial protective response in vivo. Although there are no good animal models of human CFHR activities, inclusion of human neutrophils can provide a more complete analysis of the relationship between serum complement-bactericidal activity and bacterial killing (see for instance Ross et al, J Infect Dis. (1987) 155 (6): 1266-1275). The authors should perform such combined serum- and cell-based assays in which a more complete role of complement and in particular its C3 fragment receptors on neutrophils can be evaluated for their contribution to bacterial killing.
This is an interesting suggestion. Marked susceptibility to meningococcal disease is seen in individuals with rare complement defects (especially loss of components of the terminal pathway, which is necessary for bacteriolysis and not opsonphagocytosis), those receiving C5 inhibitors (i.e. eculizumab), and inherited defects of the AP (i.e. properdin and factor D deficiencies). Furthermore, the established correlate of protection against meningococcal disease is the presence in the serum of bactericidal antibodies (i.e. antibodies that trigger the classical complement pathway and cause bacteriolysis).
In contrast, neutropaenic patients and people unable to generate a neutrophil anti-microbial oxidative burst do not exhibit high rates of meningococcal disease. This is consistent with the detection of diplococci in neutrophils in the cerebrospinal fluid and blood of patients with meningococcal disease (the bacterium was originally named Diplococcus intracellulare) and the resistance of pathogenic Neisseria to killing by neutrophils in the laboratory (shown by us and others, e.g., Mol Microbiol. 2011 Sep;81(5):1330-42; Nat Rev Microbiol. 2012 Jan 31;10(3):178-90). Work cited by the reviewer used a large number of uncharacterised bacterial strains and no details were provided about the method of recovery of neutrophils (which affects their activation status/NET formation).
Therefore neither genetic, clinical nor laboratory evidence implicates polymorphonuclear leukocytes and opsonphagocytosis in innate immunity against the meningococcus. Therefore work with polymorphonuclear leukocytes would not contribute any further insights into the effects of CFHRs. However, in line with the reviewers’ comments, we now discuss this point in the manuscript.
4) CFH and CFHR3 are generally considered to have similar function of negatively regulating the complement activity. However, the authors indicate here and in previous studies that this perception is wrong and CFHR3 can compete with CFH to bind to C3b complex and therefore counteract the negative function of CFH. The authors should go beyond the erythrocyte haemolysis assay in Figure 1b and examine the general function of CFHR3 in serum-mediating killing of bacteria that have nothing to do with CFH/CFHR3 binding (also consider using their CFHR3-deficient sera). This is particularly important in that pathogens exhibit a wide variety of mechanisms to evade the in vivo immune response, most of which do not directly target the complement system. In that context, additional support for an important role by this mechanism would add substantially to the relevance and potential impact of the study.
Our hypothesis, supported by the data in Figure 1, is that CFHR3 has no activity except in its ability to compete for the same binding sites as CFH. This is now further supported by the additional demonstration that CFHR3 per se has no effect on complement-mediated lysis in the absence of CFH (see Figure 1–figure supplement 1 and the answer to point 5 below). As suggested by the reviewer, to further exemplify this point we have now examined serum-mediated killing of E. coli since these do not express any CFH binding protein. These new data (now incorporated into Figure 3–figure supplement 2, panel b) clearly demonstrate that addition of CFHR3 has no direct effect on killing of this bacterium.
5) According to the authors' model, the function of CFHR3 should depend on the presence of CFH. However, there were no direct evidences demonstrating this point. Can CFH-deficient serum be found? If not, is it possible to deplete or block CFH by using CFH-specific antibody? In the latter, the authors can then examine whether exogenous CFHR3 still has any effect on complement-mediated killing in the sera in the absence of CFH function.
Working with CFH-deficient sera is difficult as it is prone to full complement activation following relatively minor insult. However, as suggested, we have now repeated the haemolytic assays in CFH-deficient sera and show that addition of CFHR3 has no effect on haemolysis in the absence of CFH (new Figure 1–figure supplement 1). Furthermore, reconstitution of the sera with CFH restores the ability of CFHR3 to promote haemolysis.https://doi.org/10.7554/eLife.04008.015
- Joseph JE Caesar
- Susan M Lea
- Christoph M Tang
- Philip N Ward
- Christoph M Tang
- Susan M Lea
- Hayley Lavender
- Christoph M Tang
- Susan M Lea
- Talat H Malik
- Matthew C Pickering
- Elena Goiecoechea De Jorge
- Christoph M Tang
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
JJEC and RME are funded by Wellcome Senior Investigator Awards to SML (100298) and CMT (102908), respectively, PNW by the Oxford Martin School Vaccine Design Institute, HL by an MRC programme grant G0900888 to CMT and SML. MCP is a Wellcome Trust Senior Fellow in Clinical Science (WT082291MA) and THM is funded by this fellowship. EGdeJ is funded by an Imperial College Research Fellowship. We thank Nicola Ruivo for technical assistance. Work in CMT’s lab is funded by Wellcome Trust Investigator award (WT102908MA), a Programme grant from the MRC (G0900888), The Oxford Martin School and EUCLIDS (FP7 GA no. 279185).
Human subjects: Tissue samples (in this study sera) were provided by the Imperial College Healthcare NHS Trust Tissue Bank (ICHTB). Other investigators may have received samples from these same tissues. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Volunteers were provided with the study information sheet (Donating Biological Samples for Research - Information for Donors, www1.imperial.ac.uk/tissuebank/tissuecollection/healthyvolunteers/) and informed consent obtained. ICHTB is approved by National Research Ethics Service to release human material for research (12/WA/0196).
- Feng Shao, National Institute of Biological Sciences, China
- Received: July 15, 2014
- Accepted: November 25, 2014
- Version of Record published: December 23, 2014 (version 1)
© 2014, Caesar et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.